無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

毛細血管拡張性運動失調症 (Louis-Bar症候群):世界の治験動向

Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 170833
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
毛細血管拡張性運動失調症 (Louis-Bar症候群):世界の治験動向 Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017
出版日: 2017年04月30日 ページ情報: 英文 43 Pages
概要

当レポートでは、毛細血管拡張性運動失調症 (Louis-Bar症候群) 治療薬に関する治験の最新動向について分析しており、G7 (主要7カ国) 諸国およびE7 (新興7カ国) における治験件数、被験者数、有望なスポンサー、治験に携わっている主な企業や機関、有望な薬剤の情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系疾患治療薬の治験における毛細血管拡張性運動失調症 (Louis-Bar症候群) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患治療薬の治験における毛細血管拡張性運動失調症 (Louis-Bar症候群) の割合

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

毛細血管拡張性運動失調症 (Louis-Bar症候群) 治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

目次

GlobalData's clinical trial report, "Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Ataxia-Telangiectasia (Louis-Bar Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Ataxia-Telangiectasia (Louis-Bar Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 40

  • Abbreviations 40
  • Definitions 40
  • Research Methodology 41
  • Secondary Research 41
  • About GlobalData 42
  • Contact Us 42
  • Source 43

List of Tables

List of Tables

  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 14
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 17
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27

List of Figures

List of Figures

  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Ataxi
Back to Top